The oral LD50 in mouse and rat was >3 mg/kg. The intravenous LD50 in rat was also >3 mg/kg.L40734
There is limited information regarding filgrastim overdose. The maximum tolerated dose of filgrastim has not been determined. In clinical trials of patients with cancer receiving myelosuppressive chemotherapy‚ white blood cell counts greater than 100,000/mm3 have been reported in less than 5% of patients‚ but were not associated with any reported adverse clinical effects. Patients in the bone marrow transplantation studies received up to 138 mcg/kg/day without toxic effects‚ although there was a flattening of the dose response curve above daily doses of greater than 10 mcg/kg/day.L40714
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli.L40714 Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood.L40719 It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis in patients undergoing peripheral blood progenitor cell collection and therapy.L40714
Filgrastim was approved in the US in 1991 and there are biosimilars available with similar therapeutic indications.A245858 Tbo-filgrastim was approved by the FDA on August 29, 2012.L36325 Filgrastim-sndz was approved on March 6, 2015 L40768 and filgrastim-ayow was approved on March 2, 2022.L40773 A long-acting, pegylated G-CSF, pegfilgrastim, was made available to increase the duration of action of the drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Bleomycin | The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin. |
| Cyclophosphamide | The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide. |
| Topotecan | The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan. |
| Vindesine | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vindesine. |
| Vinorelbine | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinorelbine. |
| Vincristine | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine. |
| Vinblastine | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinblastine. |
| Vintafolide | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vintafolide. |
| Vinflunine | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinflunine. |
| Vincamine | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincamine. |